Table S1.
Model parameter estimates for select PRO measures among study completers and all participants
| Model parameter | Completers (MMRM) | All participants (MMRM) | All participants (JPSM) | |||
|---|---|---|---|---|---|---|
| Estimate | p-value | Estimate | p-value | Estimate | p-value | |
| SF-36v2 PCS | ||||||
| Intercept | 49.540 | <0.001 | 50.009 | <0.001 | 50.036 | 0.001 |
| Visit | 0.041 | 0.764 | 0.013 | 0.917 | 0.020 | 0.911 |
| RO120 vs DN | −3.654 | 0.100 | −0.797 | 0.619 | −0.810 | 0.611 |
| RO90 vs DN | 0.877 | 0.693 | 2.488 | 0.127 | 2.507 | 0.122 |
| ROPL vs DN | 1.846 | 0.591 | −0.409 | 0.815 | −0.670 | 0.702 |
| Visit*RO120 vs DN | 0.845 | 0.099 | 0.668 | 0.159 | 0.674 | 0.147 |
| Visit*RO90 vs DN | −1.091 | 0.033 | −1.136 | 0.018 | −1.146 | 0.014 |
| Visit*ROPL vs DN | −0.294 | 0.709 | −0.664 | 0.303 | −0.519 | 0.420 |
| SF-36v2 MCS | ||||||
| Intercept | 47.187 | <0.001 | 46.203 | <0.001 | 46.264 | <0.001 |
| Visit | −0.029 | 0.868 | 0.113 | 0.487 | 0.054 | 0.826 |
| RO120 vs DN | −0.723 | 0.783 | −2.542 | 0.201 | −2.804 | 0.160 |
| RO90 vs DN | −4.016 | 0.128 | −0.748 | 0.711 | −0.728 | 0.720 |
| ROPL vs DN | −0.326 | 0.936 | −0.556 | 0.798 | −0.286 | 0.897 |
| Visit*RO120 vs DN | 0.432 | 0.515 | 0.388 | 0.535 | 0.513 | 0.400 |
| Visit*RO90 vs DN | −0.135 | 0.839 | −0.478 | 0.450 | −0.501 | 0.412 |
| Visit*ROPL vs DN | −0.281 | 0.784 | −0.662 | 0.437 | −0.921 | 0.277 |
| SWN-S | ||||||
| Intercept | 90.239 | <0.001 | 89.862 | <0.001 | 90.014 | <0.001 |
| Visit | 0.222 | 0.351 | 0.243 | 0.273 | 0.072 | 0.799 |
| RO120 vs DN | 1.801 | 0.662 | −1.000 | 0.743 | −1.157 | 0.704 |
| RO90 vs DN | −8.265 | 0.046 | −4.568 | 0.141 | −4.621 | 0.136 |
| ROPL vs DN | −6.439 | 0.313 | −3.018 | 0.366 | −3.515 | 0.295 |
| Visit*RO120 vs DN | −0.196 | 0.827 | −0.389 | 0.649 | −0.336 | 0.688 |
| Visit*RO90 vs DN | −0.302 | 0.735 | −0.302 | 0.726 | −0.300 | 0.722 |
| Visit*ROPL vs DN | 1.494 | 0.281 | −0.632 | 0.591 | −0.502 | 0.671 |
| MSQ | ||||||
| Intercept | a | NA | 0.922 | <0.001 | 0.696 | <0.001 |
| Visit | 0.655 | <0.001 | 0.408 | <0.001 | 0.020 | 0.851 |
| RO120 vs DN | 2.183 | 0.003 | 0.468 | 0.256 | 0.524 | 0.213 |
| RO90 vs DN | 1.731 | 0.010 | 0.654 | 0.128 | 0.711 | 0.104 |
| ROPL vs DN | 0.967 | 0.285 | 0.220 | 0.604 | 0.261 | 0.548 |
| Visit*RO120 vs DN | −0.398 | 0.180 | −0.004 | 0.987 | −0.052 | 0.812 |
| Visit*RO90 vs DN | −0.311 | 0.284 | −0.158 | 0.499 | −0.208 | 0.341 |
| Visit*ROPL vs DN | −0.406 | 0.290 | −0.321 | 0.217 | −0.412 | 0.095 |
Notes: aThe model (MSQ, completers) including the intercept failed to converge.
Abbreviations: DN, de novo; JPSM, joint process survival model; MCS, mental component score; MMRM, mixed model for repeated measures; PCS, physical component score; MSQ, medication satisfaction questionnaire; NA, not available; PRO, patient-reported outcomes; RO120, rollover 120 mg; RO90, rollover 90 mg; ROPL, rollover placebo; SF-36v2, Short-Form 36-item Questionnaire Version 2; SWN-S, Subjective Well-being Under Neuroleptic Scale – Short Version.